Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 19/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 19/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL28644141 | 1.00 | ADRA1A (0.62) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| Oxalic Acid SCHEMBL28644138 | 1.00 | ADRA1A (0.62) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL13729913 | 0.99 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL28926323 | 0.99 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL524564 | 0.99 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL18157802 | 0.95 | ADRA1D (0.62) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| Alpha-Ketoglutaric Acid SCHEMBL17026691 | 0.94 | ADRA1D (0.58) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL28996811 | 0.91 | ADRA1D (0.66) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL13037438 | 0.91 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BHTR1AADRA2A | |
| SCHEMBL19730677 | 0.91 | ADRA1D (0.55) | ADRA1AADRA1DADRA1BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806340-B1 | INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2011-05-04 | — | — | EP | claimed |
| US-7834193-B2 | Indoline compound and process for producing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | claimed |
| US-20070197627-A1 | Indoline compound and process for producting the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | claimed |
| EP-1806340-A1 | INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-11 | — | — | EP | claimed |
| US-20180339964-A1 | THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINESALT | BIOCON LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| WO-2012014186-A1 | PROCESS FOR THE PREPARATION OF SILODOSIN AND ITS NOVEL INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| EP-1806340-B1 | INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7834193-B2 | Indoline compound and process for producing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20070197627-A1 | Indoline compound and process for producting the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1806340-A1 | INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339964-A1 | THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINESALT | BPHL, QPCT, DAO | OPRM1 1126/4885SLC6A4 798/4885ADRA1A 609/4885 |
| US-20070197627-A1 | Indoline compound and process for producting the same | BPHL, DAO, INHA | OPRM1 298/4885SLC6A4 1703/4885ADRA1A 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.